AMRX

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

时间:2025-01-23 21:00:02 市场: 美股 综合

关联: AMRX

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

时间:2024-10-21 20:00:00 市场: 美股 综合

关联: AMRX

Amneal Pharma : Truist Securities Raises Target Price to $12 From $10

时间:2024-10-02 18:55:09 市场: 综合 美股

关联: AMRX

Amneal Pharmaceuticals Inc - to Build New Facilities for Metsera's Medicines

时间:2024-10-01 18:00:00 市场: 美股 综合

关联: AMRX

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

时间:2024-10-01 18:00:00 市场: 美股 综合

关联: AMRX

Amneal Launches Crexont® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease

时间:2024-09-23 20:00:02 市场: 美股

关联: AMRX